Mesothelial hyperplasia with reactive atypia: Diagnostic pitfalls and role of immunohistochemical studies - A case report

Diagnostic Cytopathology

Volumn 22, Issue 2, 2000, Pages 113-116

  Lee, Andrea ^a   Baloch, Zubair W ^a   Yu, Gordon ^a   Gupta, Prabodh K ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Effusion cytology; HBME 1; Immunohistochemistry; Mesothelial cells

Indexed keywords

ARTICLE; CASE REPORT; CELL HYPERPLASIA; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; LUNG CARCINOMA; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MESOTHELIUM; PERICARDIAL EFFUSION; PRIORITY JOURNAL;

ADENOCARCINOMA; CYTODIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; EPITHELIUM; FEMALE; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PERICARDIAL EFFUSION; PERICARDITIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033956240     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(200002)22:2<113::AID-DC12>3.0.CO;2-6     Document Type: Article

References (22)

1. Naylor B. Pleural, peritoneal and pericardial fluids. In Bibbo M, ed. Comprehensive Cytopathology. Philadelphia: W.B. Saunders. 1991;24: 551-621.
2. Battifora H, McCaughey WTE. Tumors of the serosal membranes. Third series, fascicle 15. Washington, DC: Armed Forces Institute of Pathology; 1995.
3. Crome L. Squamous metaplasia of the peritoneum. J Pathol Bacteriol 1945;62:61-68.
4. Schatz CB, Colgan TJ. Squamous metaplasia of the peritoneum. Arch Pathol Lab Med 1991;115:397-398.
5. Gavin FM, Sutton J, Clayden DA, Banks RI, Bird CC. Morphometric differences between cytologically benign and malignant serous effusions. Acta Cytol 1988;32:175-182.
6. Duggan MA, Masters CB. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Acta Cytol 1987;31:807-814.
7. Tickman RJ, Cohen C, Varma VA, Fekete PS, DeRose PB. Distinction between carcinoma cells and mesothelial cells in serous effusions: usefulness of immunohistochemistry. Acta Cytol 1990;34:491-496.
8. Bedrossian CWM. Special stains, the old and the new: the impact of immunocytochemistry in effusion cytology. Diagn Cytopathol 1996;18: 141-149.
9. Nance KV, Silverman JF. The utility of ancillary techniques in effusion cytology. Diagn Cytopathol 1991;8:185-189.
10. Ghosh AK, Spriggs AI, Taylor-Papadimitriou J, Mason DY. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. J Clin Pathol 1983;36:1154-1163.
11. Frisman DM, McCarthy WF, Schleiff P, Buckner S, Nocito JD, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993;6:179-184.
12. Donna A, Betta Pier-G, Chiodeva P, Bellingeri D, Libener R, Zorzi F, Tassi GF. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit MAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called anti-meosthelioma antibodies. Hum Pathol 1997;28:929-937.
13. Chan JKC, Loo KT, Yau BKC, Lam SY. Nodular histiocytic/mesothelial hyperplasia: a lesion potentially mistaken for a neoplasm in transbronchial biopsy. Am J Surg Pathol 1997;21:658-663.
14. Meittinen M, Kovatich AJ. HBME-1 a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma and soft-tissue and bone tumors. Appl Immmunohistochem 1995;3:115-122.
15. Renshaw AA, Pinkus GS, Cotson JM. HBME-1 aids in distinguishing mesotheliomas and adenocarcinomas of the lung and breast. Mod Pathol 1995;8:152 [abstract].
16. Savera AT, Raju U, Linden MD. Mesothelioma vs. adenocarcinoma: diagnostic utility of HBME-1. Lab Invest 1996;74:162 [abstract].
17. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HMBE-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 1996;29:209-215.
18. Ordonez NG. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinomas: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-1408.
19. Bateman AC, Al-Talib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopatholoay 1997;30: 49-56.
20. Riera HR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21: 1409-1414.
21. Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F. Utility of HBME-1 immunostaining in serous effusions. Cytopathology 1993;8:328-335.
22. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1 and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998;84:101-108.